Microvast Holdings announces departure of chief financial officer
Director Tsai Chun-Jung of Ainos , Inc. (NASDAQ:AIMD) recently sold 25,903 shares of common stock in three separate transactions, netting a total of $13,623. The sales occurred between June 18 and June 23, 2025, with prices ranging from $0.50 to $0.5517 per share. According to InvestingPro data, AIMD’s stock has shown significant volatility with a beta of 2.22, and the company’s current market capitalization stands at $10.59 million.
On June 18, Tsai sold 5,000 shares at a price of $0.5217 per share. Followed by a sale of 10,903 shares on June 19 at $0.5517 per share. The final transaction on June 23 involved the sale of 10,000 shares at $0.50 per share. The current share price represents a 53% decline from the 52-week high of $1.07. InvestingPro analysis indicates the company is facing significant cash burn challenges, with several additional risk factors available to subscribers.
Following these transactions, Tsai Chun-Jung directly owns 1,401,997 shares of Ainos, Inc. The company’s overall financial health score is rated as "Weak" by InvestingPro, which has identified multiple additional insights about the company’s performance and outlook.
In other recent news, Ainos, Inc. reported its first revenue from the deployment of its AI Nose technology in Japan’s senior care sector, with a notable 412% increase in Q1 revenue year-over-year. The company also received regulatory approval in Taiwan to begin human clinical trials for its VELDONA oral interferon treatment, with patient enrollment expected in the second half of 2025. Ainos has partnered with Japanese robotics firm ugo, Inc. to integrate its smell detection technology into service robots, with field testing scheduled in Japan later this year. Additionally, Ainos is collaborating with ASE to incorporate AI Nose technology into smart factory operations, with pilot deployments planned at ASE facilities.
The AI Nose platform, which digitizes scents into structured data, has shown improved accuracy in elder care applications, increasing from 80% to 85% accuracy across over 2,000 data samples. The platform’s ability to detect excretion odors is critical for non-contact hygiene monitoring in long-term care facilities, a growing need in aging populations like Japan and Taiwan. Ainos aims to expand its technology to classify everyday scents such as meat, food, and beverages, with preliminary accuracy exceeding 90%. The partnership with ugo aims to create humanoid robots with a functional sense of smell, enhancing the robots’ ability to perceive their environment.
The global electronic nose market, including Ainos’ SmellTech, is projected to grow significantly, from $29.8 billion in 2025 to $76.5 billion by 2032. This growth is driven by the healthcare sector’s increasing adoption of AI-powered scent detection technologies. These developments position Ainos as a key player in the emerging SmellTech market, with potential applications across healthcare, industry, and consumer sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.